The Benefits of an Immune-Directed ADC Strategy

Traditional autoimmune and inflammatory treatments have historically relied on what experts describe as a “carpet bombing strategy,” which provides efficacy but causes significant collateral damage to healthy tissue. According to Arthur Tzianabos, CEO, Lifordi Immunotherapeutics, while steroids are a $10 billion market, patients often cannot tolerate them long-term because they “hit not only the disease, but also a lot of other normal, healthy tissue,” leading to numerous side effects. This has prompted an industry-wide shift toward “precise targeting of the immune system” through the use of antibody-drug conjugates (ADCs).

VISTA, according to…